Idexx Laboratories Inc's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Idexx Laboratories Inc's ROA in the third quarter of 2026?
Idexx Laboratories Inc achieved a return on average assets (ROA) of 34.05 % in its third quarter of 2026 a new company high.

Despite the company's net income deteriorating, Idexx Laboratories Inc was able to improve its ROA compared to the second quarter of 2026.

However, within the Healthcare sector 28 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 117, from total ROA ranking in the second quarter of 2026 at 145.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	9.46 %	3.35 %	5.35 %	5.41 %	4.8 %
Y / Y Net Income Change	15.49 %	15.11 %	14.74 %	14.82 %	17.94 %
Net Income (TTM) in million	1,182	1,140	1,095	1,059	1,027
Return On Assets (TTM)	34.05 %	33.61 %	32.56 %	31.91 %	31.35 %
IDXX's Total Ranking	# 117	# 145	# 144	# 135	# 153
Total Assets (TTM) in million	3,707	3,442	3,385	3,351	3,387
Seq. Total Assets Change	7.69 %	1.68 %	1.04 %	-1.06 %	1.68 %
Seq. Net Income Change	-6.28 %	21.54 %	12.19 %	-9.62 %	-6.59 %

IDXX's 5 Years Annual ROA >> Back to IDXX Management Effectiveness >> Compare IDXX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 0
Sector	# 29
Overall	# 108

Return On Assets Statistics
High	Average	Low
34.05 %	22.58 %	12.04 %
(Sep 30 2026)		(Sep 30 2015)

Financial Statements
Idexx Laboratories Inc's Assets	$ 3,707 million	IDXX's Balance sheet
Idexx Laboratories Inc's Income	$ 317 million	Quarterly IDXX's Income Statement
IDXX's Income by Division		See IDXX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	5.41 %	1.05 %	19.6 %	7.93 %	6.22 %
Total Assets in million	3,351	3,179	3,146	2,630	2,437
Y / Y Net Income Change	19.33 %	5.07 %	24.44 %	-8.83 %	27.95 %
Net Income in million	1,059	888	845	679	745
Annual Return On Assets	31.62 %	27.93 %	26.86 %	25.82 %	30.56 %

IDXX's 5 Years Annual ROA >> Back to IDXX Management Effectiveness >> Compare IDXX ROA to its Competitors

Comment on IDXX's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 31.62 % compared to prior year, due to annual net income growth of 19.33 % to $1,059.46 million, while value of Idexx Laboratories Inc's overall assets grew just by 5.41 % to $3,350.76 million, compared to $3,350.76 a year before.

More Return On Assets Ratios
IDXX's' Return on Assets at Yahoo Finance
In Vitro & In Vivo Diagnostic Substances Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IDXX's Roa Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IDXX's Competitors
Subscribers only: Roa for Idexx Laboratories Inc's Suppliers
Subscribers only: Return On Assets for IDXX's Customers

You may also want to know
IDXX's Roi	IDXX's Inventory Turnover Ratio	IDXX's Growth Rates	IDXX's Dividend Comparisons
	IDXX's Profitability Ratios	IDXX's Asset Turnover Ratio	IDXX's Dividend Growth
IDXX's Roe	IDXX's Valuation Ratios	IDXX's Financial Strength Ratios	IDXX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Arbutus Biopharma Corp	89.26 %
Exelixis Inc	63.88 %
Rigel Pharmaceuticals Inc	59.56 %
Lensar Inc	46.55 %
Alnylam Pharmaceuticals Inc	46.08 %
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Protalix Biotherapeutics inc	19.89 %
Electromed Inc	19.73 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %

Date modified: 2026-11-03T10:00:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.